Skip to content

Journal · Hereditary Cancer · Updated 15 November 2026

Familial Cancer

Read Familial Cancer research on DeepDyve. No university library needed.

Familial Cancer, published by Springer Nature, has covered research on inherited cancer risk since 2000. Its papers study the genes that predispose families to cancers such as colorectal and pancreatic cancer, along with genetic testing, counseling and reports of rare inherited variants. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Familial Cancer
Journal cover

Familial Cancer at a glance

Full title
Familial Cancer
Abbreviation (NLM)
Fam Cancer
Publisher
Springer Nature
Print ISSN
1389-9600
Online ISSN (eISSN)
1573-7292
First published
2000
Subjects
Neoplasms
Access model
Hybrid: subscription, with an open access option
On DeepDyve
Research articles; availability varies by article

Ways to access Familial Cancer

53% of the articles Familial Cancer published from January 1 to November 14, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 53% of Familial Cancer articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Familial Cancer. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Familial Cancer articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent Familial Cancer research worth reading

Published June to August 2026. Summaries describe what the authors report.

  1. LitStreamHereditary cancer · Colorectal cancer

    RPS20 as a colorectal cancer predisposition gene: an integrated review of the literature and evaluation in 9738 cases and 161,403 controls

    Looking for RPS20 variants in whole-genome data from 9,738 colorectal cancer cases and 161,403 controls, the authors found one putative loss-of-function variant in cases and none in controls, and conclude that the combined data do not conclusively show RPS20 is a predisposition gene.

    Familial Cancer, June 2026 · DOI 10.1007/s10689-026-00582-z

  2. LitStreamHereditary cancer · TP53 variants

    Homozygous TP53 alterations: a case of a biallelic splice variant and a brief review of the literature

    The authors describe a girl born to first-cousin parents who had an early, aggressive choroid plexus carcinoma and died at age 4, and who carried two copies of a TP53 splice variant for which both parents were heterozygous carriers.

    Yildirim et al. · Familial Cancer, published online June 12, 2026 · DOI 10.1007/s10689-026-00580-1

  3. LitStreamHereditary cancer · Pancreatic cancer

    Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain

    Reviewing 223 pancreatic cancer patients given rapid germline testing ordered by their oncologists at a Madrid hospital, the authors report pathogenic variants in 32 (14.3%), treatment changes in 7 patients (3%), and a median of 48 days from test request to results.

    Bringas et al. · Familial Cancer, published online August 1, 2026 · DOI 10.1007/s10689-026-00595-8

See every Familial Cancer article on DeepDyve

Questions about Familial Cancer

How can I read Familial Cancer articles without a subscription?

53% of Familial Cancer articles published from January 1 to November 14, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Familial Cancer articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Familial Cancer?

Familial Cancer’s NLM (PubMed) abbreviation is Fam Cancer.

What is the ISSN of Familial Cancer?

The print ISSN is 1389-9600 and the online ISSN is 1573-7292.

Is Familial Cancer open access?

Familial Cancer is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 49 of 93 Familial Cancer articles (53%) carry a Creative Commons license, per Crossref.

Familial Cancer articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.

Start reading Familial Cancer today

One month free, then less than $2 a day. Familial Cancer, plus millions of articles from thousands of journals.

Start free month

Like this: